share_log

Femasys | 8-K: Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

Femasys | 8-K: Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

Femasys | 8-K：Femasys公布截至2024年3月31日的季度财务业绩并提供公司最新情况
美股sec公告 ·  05/09 08:37
Moomoo AI 已提取核心信息
On May 9, 2024, Femasys Inc., a biomedical company specializing in women's health solutions, reported its financial outcomes for the first quarter ending March 31, 2024, and provided a corporate update. The company disclosed a net loss of $3,599,510, or $0.17 per share, compared to a net loss of $2,946,257, or $0.25 per share, in the same period the previous year. Research and development expenses rose to $1,770,731, while sales saw a slight decrease. Despite the net loss, Femasys highlighted positive developments, including promising data from the pivotal trial of its FDA-cleared FemaSeed product for infertility treatment and the initiation of a pivotal trial for FemBloc, a non-surgical permanent birth control solution. The company appointed Richard Spector as Chief Commercial Officer and announced the first in-office commercial procedure with FemaSeed. Femasys also reported having sufficient cash to fund operations into the second half of 2025. The full financial details were made available in the company's Form 10-Q filed on May 9, 2024.
On May 9, 2024, Femasys Inc., a biomedical company specializing in women's health solutions, reported its financial outcomes for the first quarter ending March 31, 2024, and provided a corporate update. The company disclosed a net loss of $3,599,510, or $0.17 per share, compared to a net loss of $2,946,257, or $0.25 per share, in the same period the previous year. Research and development expenses rose to $1,770,731, while sales saw a slight decrease. Despite the net loss, Femasys highlighted positive developments, including promising data from the pivotal trial of its FDA-cleared FemaSeed product for infertility treatment and the initiation of a pivotal trial for FemBloc, a non-surgical permanent birth control solution. The company appointed Richard Spector as Chief Commercial Officer and announced the first in-office commercial procedure with FemaSeed. Femasys also reported having sufficient cash to fund operations into the second half of 2025. The full financial details were made available in the company's Form 10-Q filed on May 9, 2024.
2024年5月9日，专门从事女性健康解决方案的生物医学公司Femasys Inc. 报告了截至2024年3月31日的第一季度财务业绩，并提供了公司最新情况。该公司披露的净亏损为3599,510美元，合每股亏损0.17美元，而去年同期的净亏损为2,946,257美元，合每股亏损0.25美元。研发费用上升至1,770,731美元，而销售额略有下降。尽管出现净亏损，但Femasys还是强调了积极的进展，包括美国食品药品管理局批准的FemaSeed不孕症治疗产品关键试验的令人鼓舞的数据，以及非手术永久性节育解决方案FembLOC的关键试验的启动。该公司任命理查德·斯佩克特为首席商务官，并宣布了与FemaSeed合作的第一个办公室内商业程序。Femasys还报告称，有足够的现金为2025年下半年的运营提供资金。完整的财务细节已在该公司于2024年5月9日提交的10-Q表格中公布。
2024年5月9日，专门从事女性健康解决方案的生物医学公司Femasys Inc. 报告了截至2024年3月31日的第一季度财务业绩，并提供了公司最新情况。该公司披露的净亏损为3599,510美元，合每股亏损0.17美元，而去年同期的净亏损为2,946,257美元，合每股亏损0.25美元。研发费用上升至1,770,731美元，而销售额略有下降。尽管出现净亏损，但Femasys还是强调了积极的进展，包括美国食品药品管理局批准的FemaSeed不孕症治疗产品关键试验的令人鼓舞的数据，以及非手术永久性节育解决方案FembLOC的关键试验的启动。该公司任命理查德·斯佩克特为首席商务官，并宣布了与FemaSeed合作的第一个办公室内商业程序。Femasys还报告称，有足够的现金为2025年下半年的运营提供资金。完整的财务细节已在该公司于2024年5月9日提交的10-Q表格中公布。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息